National Academies Press, Jan 15, 1991 - Medical - 345 pages
The abortifacient RU-486 was born in the laboratory, but its history has been shaped by legislators, corporate marketing executives, and protesters on both sides of the abortion debate.
This volume explores how society decides what to do when discoveries such as RU-486 raise complex and emotional policy issues. Six case studies with insightful commentary offer a revealing look at the interplay of scientists, interest groups, the U.S. Congress, federal agencies, and the public in determining biomedical public policy--and suggest how decision making might become more reasoned and productive in the future.
The studies are fascinating and highly readable accounts of the personal interactions behind the headlines. They cover dideoxyinosine (ddI), RU-486, Medicare coverage for victims of chronic kidney failure, the human genome project, fetal tissue transplantation, and the 1975 Asilomar conference on recombinant DNA.
What people are saying - Write a review
We haven't found any reviews in the usual places.
The Food and Drug Administration and DDI
A Political History of RU486
The Formation of Federal Policies in the United States 19861990
Deliberations of the Human Fetal Tissue Transplantation Research Panel
The End of the Beginning
Other editions - View all
abortion pill activists agencies AIDS AMENDMENTS OF 1972 approval Asilomar Berg bill biomedical research budget cancer Center chromosomes clinical trials Cold Spring Harbor conference congressional consensus contraceptive controversy costs debate decision DeLisi DHHS/NIH dialysis director discussion DNA sequencing drug early release effort ethical experience federal Fetal Tissue Transplantation funding gene genetic genetic linkage mapping genome research Glasow groups HFTTR HHMI Hoechst human fetal tissue human genome project involved issues kidney disease laboratories legislation Maxine Singer Medical Medicare Medicine meeting million molecular biology moral National Institutes National Right NRLC Office organizations parallel track participants patients Paul Berg plasmids political Professor proposed prostaglandin question recombinant DNA RESEARCH PANEL risk Roussel Sakiz scientific scientists SECURITY AMENDMENTS Senate social staff Technology Tissue Transplantation Research treatment U.S. Congress United United Press International University Watson Wyngaarden